<DOC>
	<DOCNO>NCT00618982</DOCNO>
	<brief_summary>Sorafenib new drug , approve brand name Nexavar treatment advance kidney cancer . It also currently test various cancer . Sorafenib work stop development new cancer cell new blood vessel . By stop growth new blood vessel around tumor , believe sorafenib prevents growth kidney cancer tumor . This `` open-label '' study mean patient , doctor Bayer Healthcare know tablets patient take . All patient study receive sorafenib tablet . Sorafenib take orally tablet ( two tablet take twice day ) . Treatment sorafenib continue patient 's tumor grow large spread patient intolerable side effect . The dose sorafenib patient receive study increase certain point patient 's treatment , long patient experience side effect patient 's tumor grown .</brief_summary>
	<brief_title>Sorafenib Dose Escalation Renal Cell Carcinoma</brief_title>
	<detailed_description>Issues Outcome Measure `` Safety tolerability '' address Adverse Events section .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Age &gt; 18 year . Metastatic clear cell RCC ( renal cell carcinoma ) Subjects least one unidimensional measurable lesion . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Memorial Sloan Kettering Cancer Center ( MSKCC ) good intermediate category Life expectancy least 12 week . Adequate bone marrow , liver renal function assess follow laboratory requirement conduct within 7 day prior treatment Signed informed consent must obtain prior study specific procedure . Subjects must receive prior systemic anticancer therapy treatment renal cell carcinoma Prior total nephrectomy History cardiac disease History human immunodeficiency virus ( HIV ) infection chronic hepatitis B C Active clinically serious infection ( &gt; grade 2 National Cancer InstituteCommon Terminology Criteria Adverse Events [ NCICTCAE ] version 3.0 ) Symptomatic metastatic brain meningeal tumor unless subject &gt; 6 month definitive therapy , negative imaging study within 4 week study entry clinically stable respect tumor time study entry . Subjects evidence history bleed diathesis Deep vein thrombosis and/or pulmonary embolus within 12 month start treatment . Delayed heal wound , ulcer bone fracture Subjects preexist thyroid abnormality whose thyroid function maintain within normal range medication Subjects undergoing renal dialysis Pregnant breastfeeding subject . Women childbearing potential must negative serum pregnancy test perform within 7 day prior start treatment . Both men woman enrol trial must use adequate barrier birth control measure course trial three month completion trial . Prior adjuvant sorafenib exclude . Radiotherapy study within 3 week start study drug Major surgery within 4 week start study Investigational drug therapy outside trial within 4 week study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Kidney cancer ,</keyword>
	<keyword>Sorafenib ,</keyword>
	<keyword>Dose escalation ,</keyword>
	<keyword>No previous treatment</keyword>
</DOC>